These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination. Gorochov G; Ropers J; Launay O; Dorgham K; da Mata-Jardin O; Lebbah S; Durier C; Bauer R; Radenne A; Desaint C; Vieillard LV; Rekacewicz C; Lachatre M; Parfait B; Batteux F; Hupé P; Ninove L; Lefebvre M; Conrad A; Dussol B; Maakaroun-Vermesse Z; Melica G; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Dualé C; Ansart S; Botelho-Nevers E; Lelièvre JD; de Lamballerie X; Kieny MP; Tartour E; Paul S JAMA Netw Open; 2024 Apr; 7(4):e248051. PubMed ID: 38652471 [TBL] [Abstract][Full Text] [Related]
3. Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines. Li D; Calderone R; Nsouli TM; Reznikov E; Bellanti JA Allergy Asthma Proc; 2022 Sep; 43(5):419-430. PubMed ID: 36065108 [No Abstract] [Full Text] [Related]
4. The Healthcare Study Examines the Humoral Anti-S1 Antibody Response Following mRNA Vaccination, Comparing Individuals with and without Prior SARS-CoV-2 Infection. Staruszkiewicz M; Pituch-Noworolska A; Skayne M; Matthias T; Skoczen S Arch Immunol Ther Exp (Warsz); 2024 Jan; 72(1):. PubMed ID: 39146978 [TBL] [Abstract][Full Text] [Related]
5. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination. Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH; Front Immunol; 2024; 15():1390022. PubMed ID: 38698851 [TBL] [Abstract][Full Text] [Related]
7. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972 [TBL] [Abstract][Full Text] [Related]
8. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G Front Immunol; 2021; 12():737083. PubMed ID: 34539673 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV. Liu WD; Lin MS; Sun HY; Shih MC; Chuang YC; Huang YS; Lin KY; Li GC; Wu PY; Chen LY; Liu WC; Su YC; He PC; Chen YT; Lin CY; Cheng YC; Yao Y; Yeh YC; Liu CC; Pan MY; Luo YZ; Chang HY; Wang JT; Sheng WH; Hsieh SM; Chang SY; Hung CC J Microbiol Immunol Infect; 2024 Aug; 57(4):554-563. PubMed ID: 38429206 [TBL] [Abstract][Full Text] [Related]
10. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648 [TBL] [Abstract][Full Text] [Related]
11. IgG antibody levels against the SARS-CoV-2 spike protein in mother-child dyads after COVID-19 vaccination. Muñoz-Gómez MJ; Martin-Vicente M; Vigil-Vazquez S; Carrasco I; Lobo AH; Mas V; Vázquez M; Manzanares A; Cano O; Zamora C; Alonso R; Sepulveda-Crespo D; Tarancon-Diez L; Muñoz-Fernández MÁ; Muñoz-Chapuli M; Resino S; Navarro ML; Martinez I Infection; 2024 Jun; 52(3):813-824. PubMed ID: 37898587 [TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836 [TBL] [Abstract][Full Text] [Related]
13. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study. Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774 [TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity. Thomas SN; Karger AB; Altawallbeh G; Nelson KM; Jacobs DR; Gorlin J; Barcelo H; Thyagarajan B Sci Rep; 2022 May; 12(1):8890. PubMed ID: 35614113 [TBL] [Abstract][Full Text] [Related]
15. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines. Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS Front Immunol; 2021; 12():744887. PubMed ID: 34712232 [TBL] [Abstract][Full Text] [Related]
16. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961 [TBL] [Abstract][Full Text] [Related]
17. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP Front Immunol; 2021; 12():781280. PubMed ID: 34987509 [TBL] [Abstract][Full Text] [Related]
18. Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2. Murayama G; Kusaoi M; Horiuchi Y; Tabe Y; Naito T; Ito S; Yamaji K; Tamura N J Infect Chemother; 2024 Oct; 30(10):1021-1027. PubMed ID: 38570139 [TBL] [Abstract][Full Text] [Related]